Navigation Links
AstraZeneca and Abbott End License Agreement for the Development of CERTRIAD
Date:12/22/2010

WILMINGTON, Del., Dec. 22, 2010 /PRNewswire/ -- AstraZeneca (NYSE: AZN) announced today that it has notified Abbott that it will discontinue the development of CERTRIAD™ (rosuvastatin calcium and fenofibric acid), which was being investigated for the treatment of mixed dyslipidemia. This means the co-development and license agreement with Abbott will end on January 22, 2011.  

A Complete Response Letter (CRL) for the CERTRIAD New Drug Application (NDA) was received from the U.S. Food and Drug Administration (FDA) on March 30, 2010.

The companies reached this decision after careful review and consideration of the CRL and the resulting regulatory delay, and have determined that the development of CERTRIAD is no longer commercially attractive.  

AstraZeneca will continue to focus on other development priorities both within and outside of the cardiovascular disease therapeutic area.

NOTES TO EDITORS:

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines.  As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of $32.8 billion in 2009.  In the United States, AstraZeneca is a $14.8 billion healthcare business.   

For more information about AstraZeneca in the US or our AZ&Me™ Prescription Savings programs, please visit: www.astrazeneca-us.com or call 1-800-AZandMe (292-6363).


'/>"/>
SOURCE AstraZeneca
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
2. New Analysis of METEOR Study Demonstrate Effects of AstraZenecas CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease
3. AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer
4. AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression
5. AstraZeneca Submits an sNDA for SYMBICORT(R) for COPD Indication
6. Volcano Announces Participation in SATURN Clinical Trial Sponsored by AstraZeneca
7. AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines
8. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
9. AstraZeneca Submits sNDA for NEXIUM(R) I.V. for Peptic Ulcer Bleed Indication
10. Phase III Study of Abbotts Investigational TriLipix(TM) in Combination With AstraZenecas CRESTOR(R) Meets Primary Endpoints on Key Lipids
11. AstraZeneca Submits an sNDA for SYMBICORT(R) for the Treatment of Asthma in Children as Young as Age Six
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... Lilly and Company (NYSE: LLY ) today announced that ... regimen patent would not presently be infringed by Actavis marketing ... Italy and Spain ... solution.  --> --> ... that Lilly,s patent would be indirectly infringed by Actavis marketing ...
(Date:2/12/2016)... februari 2016 AAIPharma Services Corp./Cambridge ... van productie en ontwikkeling op maat voor ... een uitbreiding aan van steriele vul- en ... Charleston, SC . Substantiële ... recente investeringen. http://photos.prnewswire.com/prnh/20150806/256637LOGO ...
(Date:2/12/2016)... 12, 2016 --> ... Chronic Inflammation Global Clinical Trials Review, H2, 2015 ... global clinical trials landscape along with top level ... Country (G7 & E7), Trial Status, Trial Phase, ... top companies involved and enlists all trials (Trial ...
Breaking Medicine Technology:
(Date:2/12/2016)... ... February 12, 2016 , ... Vail knee specialist Robert LaPrade, MD, ... in 2016 . The list consists of physicians establishing, leading and partnering with ambulatory ... , An Ambulatory Surgery Center, also known as an ASC, is a modern ...
(Date:2/12/2016)... ... February 12, 2016 , ... For Coast Dental dentist Everet Lake, DDS, ... dental assistant Terrell Moore shortly before 7 a.m. to volunteer at Friday’s Dentistry from ... their time and skills to help hundreds of uninsured and underinsured people receive much-needed ...
(Date:2/12/2016)... ... 2016 , ... Homeowners now have a next generation tool ... leading brand of building products, has improved upon its industry-best array of home ... of the ColorView® Exterior Style and Color Selector. Created expressly for the iPad®, ...
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... ... creating explosive growth in the field of long term care. With that, says ... for well-trained healthcare professionals in administrative roles in long term care environments. His ...
(Date:2/12/2016)... ... , ... Dignity Health named Dr. Scott Bingham the Facility Medical Director of ... is licensed under Dignity Health Arizona General Hospital , which opened last year ... ensure our new freestanding emergency room delivers the highest quality care to Mesa and ...
Breaking Medicine News(10 mins):